Research note
How are synthetic peptides made? Peptide synthesis and manufacturing explained
What is peptide synthesis? Explore the peptide manufacturing process, key synthesis methods, technologies, and quality factors involved in producing research peptides, from amino acid sequence design and chain assembly to purification and testing.
Most synthetic peptides for research (Insert the link after the relevant article is published) are made in a chemistry lab, not grown in cells or extracted from tissue. How are peptides made in practice? Chemists link amino acids together one at a time, usually while the chain is attached to tiny resin beads. When the chain is finished, they cut it loose, clean it up, dry it and test it. You end up with a specific sequence made to order.In simplified form, the peptide production process looks like this:Sequence design.Peptide chain assembly.Cleavage and deprotection.Purification and isolation.Analytical testing and documentation.That’s the usual chemical route, but it isn’t the only one. Some peptides are made by genetically engineered microbes, some with the help of enzymes, and some are stitched together from smaller pieces. The details also change from one molecule to the next.Below we’ll go through each stage, look at the main methods and point out where the quality of the final product actually gets decided. That last part also explains something people often wonder about: why two peptides sold under the same name can turn out to be different.
What is peptide synthesis?
Think of a peptide as a short string of beads, where each bead is an amino acid. In the lab, the beads are joined by amide bonds (in peptides they’re called peptide bonds), and that’s the heart of synthetic peptide synthesis. Each bond links the carboxyl group of one amino acid to the amino group of the next one.These bonds don’t form easily on their own. The peptide synthesis mechanism gets around this by “activating” the carboxyl group with a coupling reagent, which makes it reactive enough to attach to the next amino acid.Order matters a lot. Drop one amino acid, swap two around, or replace an L-amino acid with its mirror-image D-form, and you’ve made a different compound. Sometimes its mass changes. Sometimes the mass stays exactly the same, but the molecule takes a different shape and behaves differently.Living cells make peptides in their own way. Ribosomes read a messenger RNA template and build the chain, and enzymes may trim or decorate it afterwards. Chemical synthesis doesn’t need any of that. The chemist chooses every single building block, so it’s possible to make sequences that cells struggle with, to use amino acids that don’t occur in nature, and to add tweaks such as C-terminal amidation, ring closure (cyclisation) or labels. This flexibility is the main reason chemistry is the go-to option for the short and medium-length peptides used in research.One thing worth keeping in mind: “synthetic” only describes how a molecule was made. It tells you nothing about how pure, active or safe it is. That depends on the process and on testing.
How are research peptides made? Step-by-step peptide manufacturing process
The route below is the standard chemical one. It works a bit like a relay: each stage deals with a problem left over from the one before, and every stage affects what finally ends up in the vial.Step 1: Designing the peptide sequenceTo understand how synthetic peptides are made, start with the blueprint. Which amino acids, in which order, and does anything at the ends or on the side chains need changing? With well-known research peptides, that blueprint already exists in the published literature. For custom orders, the researcher provides it.Length is the first challenge. Add one amino acid and you add one more reaction to the process, so on a long chain the small losses stack up.Composition is the second. Some sequences are simply awkward to build. Water-repelling (hydrophobic) stretches, runs of the same amino acid, and bulky β-branched ones such as valine, isoleucine and threonine can leave growing chains sticking to each other on the resin, which slows everything down.Individual amino acids bring their own quirks: cysteine, methionine and tryptophan readily take part in side reactions, while an aspartic acid next to a glycine is practically an invitation for an unwanted by-product known as aspartimide. Anything extra – a disulfide bridge, acetylation, amidation, a fatty chain – adds more work.So the sequence on paper is only the plan. It says what to build. How hard that build turns out to be is another matter.Step 2: Selecting amino acids and preparing the synthesis systemAmino acids are a bit like puzzle pieces with too many connectors. Each one has an amino group and a carboxyl group, and many also have a reactive side chain. If all of these were left free, they’d react wherever they could, and instead of a neat chain you’d get branches and random tangles.So chemists cover the connectors they don’t want to use yet with protecting groups. There are two kinds. Temporary groups block the amino end of each new amino acid and come off after every coupling. Permanent groups guard the side chains and stay put until the whole chain is done.Then there’s the resin. In solid-phase peptide synthesis (SPPS), the first amino acid is hooked through a linker onto tiny insoluble beads. With the chain held in place, everything else – spent reagents, by-products – rinses away after each step. Bruce Merrifield worked this out in 1963, and it later earned him the Nobel Prize in Chemistry. Before that, every intermediate had to be isolated by hand, which made longer peptides painfully slow to assemble. The resin and linker also determine how the finished peptide ends: as a free acid, say, or an amide.Step 3: Building the peptide chainIn the peptide synthesis process used for standard SPPS, the chain grows backwards compared with nature, from the C-terminus towards the N-terminus. One amino acid goes on per cycle.The basic peptide synthesis steps go round in a loop:Deprotection. The temporary cap comes off the end of the chain on the resin, freeing up an amino group.Washing. The chemicals from that step are rinsed out.Coupling. The next protected amino acid is activated and attaches to the free amino group, forming a new peptide bond.Washing again. Whatever didn’t react is washed away.Some processes add a capping step as well. Any chain that failed to pick up the new amino acid gets blocked so it can’t keep growing. These stunted chains end up much shorter than the target, which makes them easier to remove later.Then the loop repeats, again and again. Once the first amino acid is on the resin, a 20-residue peptide needs 19 more couplings, and each one has to be almost perfect. Here’s why. If a coupling is 99% complete, about one chain in a hundred misses that amino acid. That sounds like very little, but over many cycles the misses pile up. Incomplete removal of the temporary caps causes similar trouble. All these faulty chains – deletion sequences, truncated chains and side-reaction products – stay on the resin next to the target right up to the end.Good reagents, carefully chosen conditions and monitoring keep the errors down. They can’t make them disappear, though, and that’s why the rest of the process exists.Step 4: Cleavage and final deprotectionOnce the last amino acid is attached, the peptide is cut off the resin. In Fmoc-based SPPS, that’s usually done with trifluoroacetic acid mixed with scavengers. The scavengers catch reactive fragments released from the protecting groups before they can damage the peptide. In most cases the same treatment also removes the permanent side-chain protection, so the peptide is released and unprotected in a single step. Boc-based chemistry uses stronger acids here. The exact conditions depend on the method, the protection strategy and the amino acids in the sequence.What you get at this point is called crude peptide. This stage of the preparation of peptides doesn’t give you a clean product. Besides the target, the crude contains chains with missing amino acids, chains that stopped short, chains still wearing some protecting groups, side-reaction products, scavenger leftovers and counter-ions from the acid. It’s rarely anywhere close to the purity researchers need.Step 5: Purifying the synthesized peptidePurification is the cleanup. The standard tool is preparative reversed-phase high-performance liquid chromatography, or RP-HPLC for short. The idea is fairly intuitive. The dissolved crude peptide is pushed through a column packed with a water-repelling material. Each component sticks to it a little differently, so as the solvent mix gradually changes, they leave the column at different times. The output is collected in portions called fractions, each one is checked, and the good ones are combined. Even the way fractions are combined is a controlled part of the process.There’s always a trade-off. Fractions at the edges of the main peak usually contain a bit of target and a bit of impurity. Keep them, and you get more peptide but lower purity. Throw them out, and purity goes up while yield goes down. With difficult sequences, only a small part of the crude may make it through purification.It’s also worth separating two things that often get mixed up: the purification step and the purity result. Running a peptide through RP-HPLC doesn’t automatically give it a certain purity. The actual number comes from analytical testing of the final pooled material.Step 6: Isolation and lyophilizationOnce purification is done, the peptide is still floating in a mix of water and organic solvent, so it has to be pulled out of there. Lyophilization, or freeze-drying, is the usual answer. The solution is frozen, then put under vacuum, and the ice goes straight to vapour without passing through a liquid stage. What’s left behind is dry: a powder, or sometimes a light cake.That’s the form most research peptides arrive in. Water is what many degradation reactions need, so removing it tends to help the material survive storage and shipping, though the benefit varies with the peptide and the formulation. Manufacturers sometimes pair isolation with a salt swap too, putting acetate in place of trifluoroacetate as the counter-ion.Even so, drying is only drying. A freeze-dried powder is not proof of sterility, stability or purity. Nor is powder the only option: some peptides are precipitated out instead, and others ship as solutions, depending on the format.Step 7: Analytical testing and batch documentationBefore a batch goes out, it’s checked against its specification. Two questions come first. Is this the right molecule, and how much of the material actually is that molecule?Identity usually falls to peptide mass spectrometry (MS). The instrument weighs the molecule and the result is checked against the mass calculated for the sequence. A match counts for a lot, but mass alone can’t spell out the full sequence or exclude every structural variant. Purity is where analytical HPLC comes in: it pulls the sample apart into its components and reports the main peak as a share of the total detected peak area. Beyond those two, a specification may call for net peptide content, water, counter-ions, residual solvents, amino acid analysis or, for certain uses, endotoxins.The results are recorded for that particular batch and often summarised in a certificate of analysis, or COA. A typical COA lists the product name and sequence, the batch or lot number, the test dates, the methods, the results and the acceptance limits.How much testing is done depends on the product and what it’s meant for. Not every batch goes through every test that exists, so it’s important to check peptide COA documentation to see what was actually measured.
Main methods of synthetic peptide production
There’s no single best peptide synthesis procedure or route. It comes down to the molecule (how long it is and what it’s made of), how much of it is needed, and what the process costs at that scale.
Solid-phase peptide synthesis (SPPS)
This is the method described above: the chain is built on resin through repeated cycles of deprotection and coupling. Because the peptide is anchored, chemists can use extra reagent to push each reaction as far as possible and then simply rinse the excess away. There’s no need to isolate the intermediate after every step. The cycle is so repetitive that machines handle it well, which is why automated synthesizers are standard equipment.This peptide synthesis technology is now routine in research labs. SPPS is the most widely used approach both for research peptides and for many approved peptide medicines.Two protection strategies dominate. Fmoc chemistry removes the temporary caps with a mild base and is the usual choice today. Boc chemistry uses acid for that step and is still used for some difficult sequences.SPPS isn’t perfect, though. Long chains, sequences that tend to clump and certain combinations of amino acids make each cycle less efficient. The method also uses a lot of reagents and solvents. For very long chains, building everything in one run often isn’t practical, so chemists switch to fragment-based approaches.
Liquid-phase peptide synthesis (LPPS)
Here the reactions happen in solution, with no resin at all. After each step, the intermediate is usually isolated and purified before the next amino acid is added. That makes the process slower and more hands-on. On the plus side, chemists can check the intermediates along the way, and for short peptides made in large amounts this approach can be cost-effective.LPPS isn’t better or worse than SPPS overall. It’s simply a better fit for some jobs, such as short sequences or fragments that will be joined together later.
Hybrid and alternative manufacturing approaches
These peptide synthesis methods are often combined. One option is to make protected fragments by SPPS and join them in solution, which is called fragment condensation. Another is chemoselective ligation: methods such as native chemical ligation join unprotected fragments and have made much longer chains possible.Some peptides skip chemistry altogether. Longer peptides and small proteins are often made by recombinant expression, where bacteria or yeast are engineered to produce them. Enzymes can also be used to form specific bonds or add modifications. Every route has its own typical impurities and its own testing needs.Keep in mind that the table compares typical features, not quality. A well-run process of any type can produce good material, and a poorly run one can fail.
What affects the quality of synthesized research peptides?
In peptide manufacturing processes, the quality of a finished batch mostly comes down to two things: how cleanly the chain was built, and how well purification removed whatever went wrong.
Incomplete synthesis and sequence-related impurities
Most impurities in a synthetic peptide aren’t random contaminants. They’re near-copies of the target, created during synthesis itself. A review of peptide-related impurities describes the main types:Deletion sequences: one amino acid is missing because a coupling or deprotection step didn’t finish.Truncated sequences: the chain stopped growing too early, for example after capping.Insertion sequences: an extra amino acid slipped in by mistake, for example through side reactions or process errors.Incompletely deprotected chains: a protecting group on a side chain survived the cleavage step.Side-reaction products: side chains changed by the reagents, or aspartimide formed at sensitive spots.Epimerization: under certain conditions, an amino acid can flip from its L-form to its mirror-image D-form. The result has exactly the same mass as the target but a different shape.Oxidation and other changes: methionine and tryptophan oxidise easily, and cysteine can form disulfide bonds where there shouldn’t be any.So even with the right sequence and a well-run process, the crude product is a mixture. The target is usually the biggest part of it, but rarely the only part.
Purification efficiency and process consistency
How easy it is to remove an impurity depends on how different it is from the target. A chain missing five amino acids is usually simple to separate. A chain missing just one, an epimer or an oxidised version can behave almost exactly like the target in the column. It may come out right next to the main peak or even hide underneath it.No two batches come out quite the same, and that’s true of manufacturing in general. Starting material quality, how heavily the resin is loaded, reaction conditions, which fractions get pooled, how the product is dried: each one nudges the outcome. What regulators want to see is that a manufacturer knows which impurities its own process throws up and holds them within set specifications.This is exactly where analytical testing earns its keep. When the same methods are used on every batch and compared against set limits, it’s easy to see whether a new batch matches the previous ones or has drifted.
Research peptides vs pharmaceutical peptides: Does manufacturing differ?
Often, the chemistry is exactly the same. That’s why any explanation of how peptides are manufactured needs to separate the synthesis itself from the rules that surround it. SPPS, LPPS, RP-HPLC purification and freeze-drying are used both for lab research materials and for active ingredients in approved medicines. Two batches of the same sequence can have an identical molecular structure, no matter which market they’re made for.The difference lies in the framework built around the chemistry. Peptide active substances in approved medicines fall under applicable good manufacturing practice (GMP) requirements and have to be backed by regulatory documentation. EU guidance on synthetic peptides lists what belongs in that dossier: the manufacturing process and its controls, starting materials, characterisation, impurity limits, analytical validation, stability data. Processes have to be qualified, any change goes through formal control, and regulation sets how detailed the documentation must be.For research materials, it’s the manufacturer who sets the specification, the documentation and the range of tests, based on the product’s intended research use. Many reputable peptide suppliers apply strict controls and detailed batch testing, and the scope of testing varies from product to product. With so much riding on the individual manufacturer, the product and its purpose, “research-grade” on its own says nothing about whether quality is higher or lower.As for the “Research Use Only” (RUO) label, it describes intended use and stops there. No claim about purity, GMP status, sterility or clinical safety is attached to it, and it isn’t a grade.Which brings us to the practical point: judge a research peptide on the evidence that comes with it, meaning batch-specific test data and documentation, not on the method’s name or the wording on the vial.
Frequently asked questions
How are peptides made in a lab?Mostly by chemical synthesis. Protected amino acids are added one at a time to a growing chain, which is usually attached to a resin. When the chain is complete, it’s cut off the resin and its protecting groups are removed. Chromatography cleans it up, then it’s dried and checked for identity and purity.What is the most common method of synthetic peptide synthesis?Solid-phase peptide synthesis (SPPS), and usually the Fmoc version of it. That’s the default for research peptides and for plenty of therapeutic ones, though not for every peptide out there. Where liquid-phase, hybrid, recombinant or enzymatic routes fit the molecule or the scale better, those get used instead.Are synthetic peptides identical to naturally occurring peptides?The sequence and chemical structure can match exactly. Differences tend to show up elsewhere: in modifications that one version carries and the other doesn’t, in counter-ions, and in whatever minor impurities each one brings along. Two products sharing a structure still aren’t the same material.Why do synthetic peptides need purification?No synthesis cycle is flawless. Couplings that don’t finish, side reactions and protecting groups that refuse to leave all generate related molecules, and those come off the resin alongside the target. Purification is how the peptide you actually want gets separated from them.Can peptide synthesis be automated?The chain-building part, yes. Synthesizers handle the repeated deprotection, coupling and washing cycles on their own, and some add heating or real-time monitoring. What stays manual is everything after that: cleavage, purification, drying and testing, all of which need people who know what they’re looking at. So automation buys speed, not a shortcut past quality control.Does a high peptide purity percentage guarantee quality?No.The peptide purity figure describes one thing: how big the main peak is next to the other peaks the detector registered. Identity, net peptide content and counter-ion level aren’t covered, impurities tucked under the main peak won’t show, and sterility and endotoxins are outside its scope entirely.
Conclusion
A synthetic research peptide is the output of a long chain of controlled steps, with SPPS as one of the main chemical methods behind it. Assembling the sequence is just the opening act. Cleavage, purification, drying and testing all leave their fingerprints on the final material, and those fingerprints show up in the batch data.Which is why a method name or a single purity number settles nothing. What’s worth looking at is the evidence tied to the batch in front of you: identity data, a purity result alongside the method that produced it, whatever else the specification covers, and paperwork that clearly connects those numbers to your material. A COA, read properly, is a report card on the manufacturing process.ReferencesBehrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4–27. doi:10.1002/psc.2836D’Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012Dawson PE, Muir TW, Clark-Lewis I, Kent SB. Synthesis of proteins by native chemical ligation. Science. 1994;266(5186):776–779. doi:10.1126/science.7973629European Medicines Agency. Guideline on the development and manufacture of synthetic peptides (EMA/CHMP/CVMP/QWP/367182/2025). Adopted by CHMP 1 December 2025; in effect from 1 June 2026. PDFHansen PR, Oddo A. Fmoc solid-phase peptide synthesis. Methods Mol Biol. 2015;1348:33–50. doi:10.1007/978-1-4939-2999-3_5Isidro-Llobet A, Álvarez M, Albericio F. Amino acid-protecting groups. Chem Rev. 2009;109(6):2455–2504. doi:10.1021/cr800323sMerrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149–2154. doi:10.1021/ja00897a025Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309–325. doi:10.1038/s41573-020-00135-8Stawikowski M, Fields GB. Introduction to peptide synthesis. Curr Protoc Protein Sci. 2012;Chapter 18:Unit 18.1. PMID: 22851497